Vericel (VCEL) Long-Term Investments (2019 - 2026)
Vericel's (VCEL) quarterly Long-Term Investments came in at $101.3 million in Q1 2026, up 22.34% year-on-year from $82.8 million in Q1 2025, and up 65.0% quarter-over-quarter from $61.4 million in Q4 2025.
Vericel (VCEL) Long-Term Investments (2019 - 2026) Analysis & Trends
Vericel has disclosed Long-Term Investments across 8 years of filings, most recently posting $101.3 million for Q1 2026.
- Long-Term Investments for Q1 2026 came in at $101.3 million, up 22.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $101.3 million (up 22.34% YoY), and the FY2025 annual result was $61.4 million, up 53.95% from the prior year.
- Long-Term Investments came in at $101.3 million for Q1 2026 at Vericel, up from $61.4 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $101.3 million in Q1 2026 to a low of $20.0 million in Q4 2022.
- The 5-year median for Long-Term Investments is $49.7 million (2025), against an average of $52.1 million.
- Across the five-year window, Long-Term Investments plunged 70.03% in 2023 and jumped 299.88% in 2024, its largest moves.
- Vericel's Long-Term Investments stood at $20.0 million in 2022, then increased by 26.66% to $25.3 million in 2023, then jumped by 57.73% to $39.9 million in 2024, then jumped by 53.95% to $61.4 million in 2025, then surged by 65.0% to $101.3 million in 2026.
- The last three Long-Term Investments figures came in at $101.3 million (Q1 2026), $61.4 million (Q4 2025), and $49.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.17 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Vericel | 2.04 Bn | 1.90 Bn | 49.27 Mn | 101.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 101.30 Mn |
| Dec 31, 2025 | 61.40 Mn |
| Sep 30, 2025 | 49.66 Mn |
| Jun 30, 2025 | 47.40 Mn |
| Mar 31, 2025 | 82.80 Mn |
| Dec 31, 2024 | 39.88 Mn |
| Sep 30, 2024 | 80.90 Mn |
| Jun 30, 2024 | 26.12 Mn |
| Mar 31, 2024 | 29.43 Mn |
| Dec 31, 2023 | 25.28 Mn |
| Sep 30, 2023 | 20.23 Mn |
| Jun 30, 2023 | 20.99 Mn |
| Mar 31, 2023 | 77.40 Mn |
| Dec 31, 2022 | 19.96 Mn |
| Sep 30, 2022 | 67.50 Mn |
| Jun 30, 2022 | 68.40 Mn |
| Mar 31, 2022 | 67.70 Mn |
| Dec 31, 2021 | 25.69 Mn |
| Sep 30, 2021 | 20.24 Mn |
| Jun 30, 2021 | 24.83 Mn |